

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference PU65949	FOR FURTHER ACTION see Form PCT/ISA/220 as well as, where applicable, item 5 below.	
International application No. PCT/IB2016/053285	International filing date (<i>day/month/year</i>) 3 June 2016 (03-06-2016)	(Earliest) Priority Date (<i>day/month/year</i>) 6 August 2015 (06-08-2015)
Applicant GLAXOSMITHKLINE INTELLECTUAL PROPERTY...		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of:

- ☒ the international application in the language in which it was filed
☐ a translation of the international application into _____, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b))

b. ☐ This international search report has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43.6**bis**(a)).

c. ☒ With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. ☐ **Certain claims were found unsearchable** (See Box No. II)

3. ☐ **Unity of invention is lacking** (see Box No III)

4. With regard to the **title**,

- ☐ the text is approved as submitted by the applicant
☒ the text has been established by this Authority to read as follows:

COMBINATIONS OF AN OX40 ANTIBODY AND A TLR4 MODULATOR AND USES THEREOF

5. With regard to the **abstract**,

- ☒ the text is approved as submitted by the applicant
☐ the text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority

6. With regard to the **drawings**,

- a. the figure of the **drawings** to be published with the abstract is Figure No. _____
☐ as suggested by the applicant
☐ as selected by this Authority, because the applicant failed to suggest a figure
☐ as selected by this Authority, because this figure better characterizes the invention
b. ☒ none of the figures is to be published with the abstract

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB2016/053285

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☒ forming part of the international application as filed:
 - ☒ in the form of an Annex C/ST.25 text file.
 - ☐ on paper or in the form of an image file.
 - b. ☐ furnished together with the international application under PCT Rule 13~~ter~~.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. ☐ furnished subsequent to the international filing date for the purposes of international search only:
 - ☐ in the form of an Annex C/ST.25 text file (Rule 13~~ter~~.1(a)).
 - ☐ on paper or in the form of an image file (Rule 13~~ter~~.1(b) and Administrative Instructions, Section 713).
2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No

PCT/IB2016/053285

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K39/395 A61K31/7008
 ADD. C07K16/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	S. KACZANOWSKA ET AL: "TLR agonists: our best frenemy in cancer immunotherapy", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 93, no. 6, 8 March 2013 (2013-03-08), pages 847-863, XP055129728, ISSN: 0741-5400, DOI: 10.1189/jlb.1012501 page 858 - page 859	1-20
X	----- WO 2004/060319 A2 (3M INNOVATIVE PROPERTIES CO [US]) 22 July 2004 (2004-07-22) the whole document	1-20
X	----- WO 03/045431 A2 (SCHERING CORP [US]) 5 June 2003 (2003-06-05) the whole document	1,6,12, 14,19,20
	----- -/--	



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 July 2016

Date of mailing of the international search report

25/07/2016

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040,
 Fax: (+31-70) 340-3016

Authorized officer

Covone-van Hees, M

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2016/053285

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JAEWOO LEE ET AL: "Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses", IMMUNOLOGY, vol. 125, no. 2, 1 October 2008 (2008-10-01), pages 229-240, XP55288582, ISSN: 0019-2805, DOI: 10.1111/j.1365-2567.2008.02833.x the whole document -----	1-20
X	WO 2015/095423 A2 (GENENTECH INC [US]; HOFFMANN LA ROCHE [CH]) 25 June 2015 (2015-06-25) the whole document -----	1-20
A	YVONNE BORDON: "Tumour immunology: Cracking the combination", THE JOURNAL OF IMMUNOLOGY, vol. 13, no. 7, 7 June 2013 (2013-06-07), pages 469-469, XP55288573, GB ISSN: 1474-1733, DOI: 10.1038/nri3481 the whole document -----	1-20
A	ROCH HOUOT ET AL: "Immunomodulating antibodies and drugs for the treatment of hematological malignancies", CANCER AND METASTASIS REVIEWS, KLUWER ACADEMIC PUBLISHERS, DO, vol. 30, no. 1, 28 January 2011 (2011-01-28), pages 97-109, XP019885789, ISSN: 1573-7233, DOI: 10.1007/S10555-011-9274-3 the whole document -----	1-20
X,P	Idit Sagiv-Barfi ET AL: "Intratumoral Injection of TLR4 Agonist (G100) Leads to Tumor Regression of A20 Lymphoma and Induces Abscopal Responses", ASH, 7 December 2015 (2015-12-07), XP55288569, Retrieved from the Internet: URL:https://ash.confex.com/ash/2015/webprogram/Paper80842.html [retrieved on 2016-07-14] the whole document -----	1-20

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2016/053285

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2004060319	A2	22-07-2004	
		AU 2003300184 A1	29-07-2004
		CA 2511538 A1	22-07-2004
		EP 1578419 A2	28-09-2005
		EP 2572714 A1	27-03-2013
		EP 2572715 A1	27-03-2013
		JP 2006512391 A	13-04-2006
		JP 2011016811 A	27-01-2011
		JP 2011105749 A	02-06-2011
		JP 2014101371 A	05-06-2014
		US 2004141950 A1	22-07-2004
		US 2009123460 A1	14-05-2009
		US 2011002946 A1	06-01-2011
		US 2011280903 A1	17-11-2011
		US 2013115228 A1	09-05-2013
		US 2016129095 A1	12-05-2016
		WO 2004060319 A2	22-07-2004
WO 03045431	A2	05-06-2003	
		AU 2002359516 A1	10-06-2003
		BR 0214457 A	21-11-2006
		CA 2468320 A1	05-06-2003
		CN 1617742 A	18-05-2005
		EP 1450858 A2	01-09-2004
		JP 2006131638 A	25-05-2006
		JP 2006502080 A	19-01-2006
		JP 2010053140 A	11-03-2010
		MX PA04004998 A	08-04-2005
		NZ 565420 A	25-09-2009
		TW 200303759 A	16-09-2003
		US 2003138413 A1	24-07-2003
		US 2009087440 A1	02-04-2009
		WO 03045431 A2	05-06-2003
		ZA 200404113 A	29-03-2006
WO 2015095423	A2	25-06-2015	
		CA 2934028 A1	25-06-2015
		US 2015190506 A1	09-07-2015
		WO 2015095423 A2	25-06-2015